Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Immunology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for NTN1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | NTN1 ECD-Fc Fusion Protein High purity (>95%), Endotoxin Controlled (<1 EU/μg). HEK293 expressed for native glycosylation. Sequence Verified. |
View NTN1 Products |
| Gene Delivery | NTN1 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and expression validation. |
View NTN1 Products |
| Benchmark Ab | Anti-NTN1 Recombinant Antibody (Biosimilar) Recombinant positive control derived from clinical-stage clone (NP137 sequence). |
View NTN1 Products |
| Validator | NTN1 siRNA Set Target-specific knockdown verification in functional cell-based assays. |
View NTN1 Products |
| Related Target A | UNC5B Receptor Protein Primary dependence receptor mediating NTN1-induced survival signals. |
View UNC5B Products |
| Related Target B | DCC Receptor Protein Co-receptor mediating netrin-1 axonal guidance and dependence receptor-induced apoptosis. |
View DCC Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species ortholog evaluation (Cyno/Mouse) | Human, Mouse, and Cynomolgus NTN1 recombinant proteins available with >95% purity |
| Subfamily off-target counter screening | Netrin family homolog panel (Netrin-3, Netrin-4) verified by mass spectrometry |
| Lack of clinical-grade positive controls | Clinical benchmark antibody (NP137 biosimilar) sequence-verified and in-house produced |
| False positive phenotype confirmation | Sequence-specific siRNA pool included for target knockdown validation |
Live NTN1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for NTN1 therapeutics is intensifying, with major players shifting focus from traditional mAbs to combination regimens and antibody-drug conjugates (ADCs). As first-generation therapies reach the clinic, the next wave of R&D is targeting the reversal of EMT (epithelial-to-mesenchymal transition) and resistance to immune checkpoint inhibitors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody | Netris Pharma | Endometrial Cancer, Non-Small Cell Lung Cancer (NSCLC) | Ligand-receptor blocking assays (Need high-purity NTN1 & UNC5B/DCC) |
| Antibody-Drug Conjugate (ADC) | Biotech Innovators | Solid Tumors (Advanced/Metastatic) | Internalization validation (Need HEK293-expressed NTN1 and stable receptor cells) |
| Combination Therapies | Netris Pharma / Roche | Uterine Cancer (with Pembrolizumab) | Synergy screening (Need robust benchmark antibodies and target validators) |